2012 - 2015 Spreading immune-reactions in esophageal cancer patients who were given cancer vaccine and whose tumors co-express additional antigens
2009 - 2011 Immunomonitoring in head and neck cancer patients treated with protein vaccine through tumor destruction
2005 - 2009 Polyvalent cancer vaccine
2000 - 2004 がん遺伝子産物由来ペプチド抗原によるがん治療
Show all
Papers (107):
Emiko Kashima, Yuka Sugimoto, Keiki Nagaharu, Eiko Ohya, Makoto Ikejiri, Yasuyuki Watanabe, Shinichi Kageyama, Koji Oka, Isao Tawara. Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation. Hematology (Amsterdam, Netherlands). 2024. 29. 1. 2392908-2392908
Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Naozumi Harada, Yoshihiro Miyahara, Hiroyoshi Hattori, Kohichi Takada, Makoto Emori, Shigeki Kakunaga, et al. O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS. Annals of Oncology. 2023. 34. S1391-S1391
Akira Kawai, Mikiya Ishihara, Tomoki Nakamura, Shigehisa Kitano, Shintaro Iwata, Kohichi Takada, Makoto Emori, Koji Kato, Makoto Endo, Yoshihiro Matsumoto, et al. Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023
Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Daisuke Muraoka, Fumiyasu Momose, Naozumi Harada, Yoshihiro Miyahara, Naohiro Seo, Hiroyoshi Hattori, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. International journal of cancer. 2023. 152. 12. 2554-2566
Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Hiroaki Ikeda, Makoto Endo, Koji Kato, Shigehisa Kitano, et al. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. BMJ open. 2022. 12. 11. e065109